Medical device manufacturer Amsino International Inc announced on Thursday that it has been awarded a contract by healthcare company Vizient for enteral syringes, effective 1 August 2026.
Amsino manufactures enteral syringes in both North America and overseas, supporting a dual-source manufacturing strategy designed to enhance supply continuity and reduce risk for healthcare providers. The programme leverages manufacturing redundancies across multiple facilities to strengthen supply chain resiliency and help ensure uninterrupted product availability during periods of market volatility or disruption.
Amsino's enteral syringe portfolio is designed to support safe and efficient enteral medication delivery and feeding practices across a variety of clinical settings.
Genprex collaborates with Roche Diagnostics on NSCLC biomarker validation
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
CelLBxHealth study highlights Parsortix potential in ADC biomarker monitoring
Coiled Therapeutics doses first patient with optimised AO-252 formulation
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
Hemogenyx partners with Lithuanian cancer centre on HG-CT-1 research and clinical programme
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184